Bicara Therapeutics (NASDAQ:BCAX) versus Assertio (NASDAQ:ASRT) Head to Head Analysis

Bicara Therapeutics (NASDAQ:BCAXGet Free Report) and Assertio (NASDAQ:ASRTGet Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Bicara Therapeutics and Assertio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bicara Therapeutics N/A N/A N/A
Assertio -25.72% -24.87% -10.87%

Valuation & Earnings

This table compares Bicara Therapeutics and Assertio”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bicara Therapeutics N/A N/A -$68.00 million N/A N/A
Assertio $119.00 million 0.53 -$21.58 million ($0.32) -2.07

Assertio has higher revenue and earnings than Bicara Therapeutics.

Insider & Institutional Ownership

49.0% of Assertio shares are held by institutional investors. 4.0% of Assertio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Bicara Therapeutics and Assertio, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicara Therapeutics 0 1 7 1 3.00
Assertio 0 0 3 0 3.00

Bicara Therapeutics currently has a consensus price target of $31.86, suggesting a potential upside of 229.46%. Assertio has a consensus price target of $2.75, suggesting a potential upside of 315.47%. Given Assertio’s higher possible upside, analysts plainly believe Assertio is more favorable than Bicara Therapeutics.

About Bicara Therapeutics

(Get Free Report)

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

About Assertio

(Get Free Report)

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.